全文获取类型
收费全文 | 26880篇 |
免费 | 2809篇 |
国内免费 | 797篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 1010篇 |
妇产科学 | 2145篇 |
基础医学 | 2251篇 |
口腔科学 | 351篇 |
临床医学 | 2898篇 |
内科学 | 6540篇 |
皮肤病学 | 427篇 |
神经病学 | 1762篇 |
特种医学 | 831篇 |
外科学 | 2941篇 |
综合类 | 2923篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2385篇 |
眼科学 | 883篇 |
药学 | 1195篇 |
2篇 | |
中国医学 | 375篇 |
肿瘤学 | 1415篇 |
出版年
2024年 | 64篇 |
2023年 | 468篇 |
2022年 | 313篇 |
2021年 | 527篇 |
2020年 | 466篇 |
2019年 | 217篇 |
2018年 | 819篇 |
2017年 | 807篇 |
2016年 | 869篇 |
2015年 | 851篇 |
2014年 | 809篇 |
2013年 | 1078篇 |
2012年 | 1417篇 |
2011年 | 1675篇 |
2010年 | 1052篇 |
2009年 | 1026篇 |
2008年 | 1201篇 |
2007年 | 1190篇 |
2006年 | 988篇 |
2005年 | 1179篇 |
2004年 | 1915篇 |
2003年 | 1812篇 |
2002年 | 1309篇 |
2001年 | 1127篇 |
2000年 | 516篇 |
1999年 | 662篇 |
1998年 | 661篇 |
1997年 | 623篇 |
1996年 | 417篇 |
1995年 | 330篇 |
1994年 | 362篇 |
1993年 | 386篇 |
1992年 | 404篇 |
1991年 | 353篇 |
1990年 | 351篇 |
1989年 | 305篇 |
1988年 | 241篇 |
1987年 | 238篇 |
1986年 | 192篇 |
1985年 | 138篇 |
1984年 | 93篇 |
1983年 | 86篇 |
1982年 | 79篇 |
1981年 | 80篇 |
1980年 | 66篇 |
1979年 | 59篇 |
1977年 | 51篇 |
1975年 | 57篇 |
1974年 | 43篇 |
1973年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
2.
3.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文
4.
5.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
6.
7.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
8.
含左氧氟沙星及卷曲霉素方案治疗耐多药肺结核近期疗效分析 总被引:21,自引:0,他引:21
目的 观察和评价含左氧氟沙星和卷曲霉素联合化疗方案在耐多药肺结核 (MDR PTB)治疗中的疗效。方法 将 177例MDR PTB患者分为治疗组 88例和对照组 89例。化疗方案 :治疗组以左氧氟沙星和卷曲霉素为主 ,联合利福喷汀、异烟肼、对氨基水杨酸钠、吡嗪酰胺 ;对照组用链霉素、乙胺丁醇 ,联用药物同治疗组 ,疗程均为 2 1个月。结果 共有 16 1例患者完成化疗疗程 ,治疗组 82例 ,痰菌阴转率 83% ;对照组 79例 ,痰菌阴转率 5 8% ;痰菌阴转率治疗组明显高于对照组 (P <0 0 1) ;治疗组病灶显效率 5 0 % ,空洞闭合率 6 3% ,治疗组优于对照组 (P <0 0 1) ;治疗组的药物不良反应率为 31% ,对照组为 35 % ,两组比较差异无显著性 (P >0 0 5 )。结论 含左氧氟沙星和卷曲霉素的方案治疗MDR PTB ,有助于痰菌阴转和病变吸收好转 ,药物不良反应低 ,值得在临床上推广应用 相似文献
9.
10.
王伏虎 《南京医科大学学报(英文版)》2002,16(2):49-64
Stroke is a debilitating disease that affects millions each year.While in many cases cerebral ischemic in jury can be limited by effectivw resuscitation or thrombolytic treatment,the injured neurons wither in a process known as delayed neuronal death(DND).Mounting evidence indicates that DND is not simply necrosis played out in slow motion but apoptosis is triggered.Of particular interest are two groups of signal proteins that participate in apoptosis-cyclin dependent kinases(CDKs) and p53-among a myriad of signaling events after an ischemic insult.Recent investigations have shown that CDKs,a family of enzymes initially known for their role in cell cycle regulation,are activated in injured neurons in DND.As for p53,new reports suggest that its up-regulation may represent a failed attempt to rescue in jured neurons,although its up-regulation was previously considered an indication of apoptosis.These observations thus rekindle an old quest to identify new neuroprotective targets to minimize the stroke damage.In this review,the author will examine the evidence that indicates the participation of CDKs and p53 in DND and then introduce pre-clinical data to explore CDK inhibition as a potential neuroprotective target.Finally,using CDK inhibition as an example,this paper will discuss the pertinent criteria for a viable neuroprotective strategy for ischemic in jury. 相似文献